Back

IDEAYA Biosciences plans Phase 3 IDE849 trial for ES-SCLC by late 2026

Verifying
  • IDEAYA Biosciences plans a Phase 3 IDE849 trial for ES-SCLC.
  • The clinical trial is scheduled to begin by the end of 2026.
  • IDEAYA reached a positive meeting with the FDA on trial design.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.